Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report - Takeaways - MDSpire

Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report

  • By

  • Man Ding

  • Bo Yin

  • Jiajia Yao

  • Yin Liu

  • Hongjuan Dong

  • Zuneng Lu

  • May 21, 2026

Share

  • 1

    A 25-year-old pregnant woman was diagnosed with AQP4+ NMOSD at 19 weeks of gestation and treated with high-dose prednisone pulse therapy.

  • 2

    Satralizumab was introduced as adjunctive therapy after four weeks, allowing for corticosteroid reduction and eventual discontinuation.

  • 3

    The patient showed marked improvement in visual field defects and delivered spontaneously at 34 weeks with stable maternal condition.

  • 4

    This case is the first reported instance in China of AQP4+ NMOSD management during pregnancy using satralizumab.

  • 5

    The findings provide clinical evidence to guide therapeutic decisions for NMOSD in pregnant patients.

Original Source(s)

Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report

  • by Man Ding, Bo Yin, Jiajia Yao, Yin Liu, Hongjuan Dong, Zuneng Lu

  • May 21, 2026

Related Content

CGRP Therapies Reduced Migraine Days

Systematic review found high-certainty evidence for several calcitonin gene–related peptide–targeted therapies

Can a Blood Count Predict Dementia?

Study explores a potential hematological risk marker using real-world data

  • May 20, 2026

  • 2 min
Asthma, Rhinitis Tied to Parkinson's Risk

A nationwide Korean cohort study found modestly higher Parkinson's disease incidence among patients with asthma or allergic rhinitis, with stronger associations observed among patients with greater allergic disease burden.